• 1.
    Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 Through 1999. Circulation. 2003;108:711716.
  • 2.
    Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4:313320.
  • 3.
    Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998;98:946952.
  • 4.
    Stewart S. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/ Paisley study. Am J Med. 2002;113:359364.
  • 5.
    Conen D, Chae CU, Glynn RJ, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA. 2011;305:20802087.
  • 6.
    Go AS. The ACTIVE Pursuit of Stroke Prevention in Patients with Atrial Fibrillation. N Engl J Med. 2009;360:21272129.
  • 7.
    Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806817.
  • 8.
    Hohnloser SH, Crijns HJGM, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668378.
  • 9.
    Wyse DG, Waldo AL, DiMarco JP, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:18251833.
  • 10.
    Van Gelder IC, Hagens VE, Bosker HA, et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347: 18341840.
  • 11.
    Van Gelder IC, Groenveld HF, Crijns HJGM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:13631373.
  • 12.
    Redfield MM. Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc. 2000;75: 790795.
  • 13.
    Kieny JR. Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J. 1992;13:12901295.
  • 14.
    Ohno M, Cheng CP, Little WC. Mechanism of altered patterns of left ventricular filling during the development of congestive heart failure. Circulation 1994;89:22412250.
  • 15.
    Fujino T, Yamashita T, Suzuki S, et al. Characteristics of congestive heart failure accompanied by atrial fibrillation with special reference to tachycardia-induced cardiomyopathy. Circ J. 2007;71: 936940.
  • 16.
    Wang TJ. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:29202925.
  • 17.
    Dries DL. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am CollCardiol. 1998;32:695703.
  • 18.
    Olsson LG. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am CollCardiol. 2006;47:19972004.
  • 19.
    Carson PE. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI102VI110.
  • 20.
    Brown AM, Sease KL, Robey JL, et al. The risk for acute coronary syndrome associated with atrial fibrillation among ED patients with chest pain syndromes. Am J Emerg Med. 2007;25:523528.
  • 21.
    ACTIVE Writing Group of the ACTIVE Investigators; Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:19031912.
  • 22.
    Schmitt J. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. EurHeart J. 2009;30:10381045.
  • 23.
    Crenshaw BS, Ward SR, Granger CB, et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am CollCardiol.1997;30:406413.
  • 24.
    Wong CK, White HD, Wilcox RG, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J. 2000;140:878885.
  • 25.
    Pizzetti F, Turazza FM, Franzosi MG, et al. GISSI-3 Investigators. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001;86:527532.
  • 26.
    Goldberg RJ, Seeley D, Becker RC, et al. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J. 1990;119:9961001.
  • 27.
    Lehto M, Snapinn S, Dickstein K, et al. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. EurHeart J. 2005;26: 350356.
  • 28.
    Kinjo K, Sato H, Ohnishi Y, et al. Prognostic significance of atrial fibrillation/atrial flutter in patients with acute myocardial infarction treated with percutaneous coronary intervention. Am J Cardiol. 2003;92:11501154.
  • 29.
    Kober L, Swedberg K, McMurray JJ, et al. Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. Eur J Heart Fail 2006;8:591598.
  • 30.
    Jabre P, Jouven X, Adnet F, et al. Atrial fibrillation and death after myocardial infarction: a community study. Circulation. 2011;123: 20942100.
  • 31.
    Menozzi C, Brignole M, Alboni P, et al. The natural course of untreated sick sinus syndrome and identification of the variables predictive of unfavorable outcome. Am J Cardiol. 1998;82:12051209.
  • 32.
    Kuga K, Yamaguchi I, Sugishita Y, et al. Assessment by autonomic blockade of age-related changes of the sinus node function and autonomic regulation in sick sinus syndrome. Am J Cardiol. 1988; 61:361366.
  • 33.
    Flaker G, Greenspon A, Tardiff B, et al. Death in patients with permanent pacemakers for sick sinus syndrome. Am Heart J. 2003; 146:887893.
  • 34.
    Klein G, Lissel C, Fuchs AC, et al. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study. Europace. 2006;8: 618624.
  • 35.
    Sharma AD, Klein GJ, Guiraudon GM, et al. Atrial fibrillation in patients with Wolff-Parkinson-White syndrome: incidence after surgical ablation of the accessory pathway. Circulation. 1985;72: 161169.
  • 36.
    Gulamhusein S, Ko P, Carruthers SG, et al. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation. 1982;65: 348–354.